Welcome to our dedicated page for Inspire Medical news (Ticker: INSP), a resource for investors and traders seeking the latest updates and insights on Inspire Medical stock.
Inspire Medical Systems develops and commercializes minimally invasive neurostimulation therapy for patients with obstructive sleep apnea. Its proprietary Inspire therapy is approved by the FDA, EU MDR and PDMA for moderate to severe obstructive sleep apnea, and product updates include the Inspire V system.
Company news commonly covers quarterly and annual results, revenue guidance, cash flow, earnings measures, reimbursement and coding developments, product launch activity, regulatory clearances such as MRI compatibility, executive changes and healthcare conference presentations.
Inspire Medical Systems (NYSE: INSP) will present at the virtual UBS Global Healthcare Conference on May 20, 2020, at 10:00 a.m. Eastern Time. The live presentation will be accessible through a webcast, with a replay available for two weeks afterward on Inspire’s Investor website. Inspire is a medical technology company specializing in innovative solutions for obstructive sleep apnea, including the first FDA-approved neurostimulation therapy for moderate to severe cases. For more information, visit www.inspiresleep.com.
Inspire Medical Systems (INSP) reported Q1 2020 revenue of $21.3 million, a 31% increase year-over-year. U.S. revenue rose 34% to $19.3 million, while European revenue increased 9% to $2.1 million. The company activated 28 new medical centers, reaching a total of 327, and completed a public offering raising $124.7 million in April. However, the COVID-19 pandemic led to postponements of implant procedures, significantly impacting operations. Inspire withdrew its full-year guidance due to uncertainties surrounding the pandemic.
Summary not available.
Summary not available.